News Update: Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer - Thomas Keane
As we start a new year, Dr. Thomas Keane provides an update on exciting news in the area of non-metastatic castration-resistant prostate cancer with the FDA granting priority review for apalutamide as a treatment for non-metastatic castration-resistant prostate cancer. Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC.
Watch Video from Charles Ryan, MD:
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide in the High-risk Nonmetastatic Castration-resistant Prostate Cancer
Read the Press Release
Thomas E. Keane, MBBCh, FRCSI, FACS